Top

Published in:

01-08-2019 | Filgrastim | Original Article

Priming with GM-CSF instead of G-CSF enhances CAG-induced apoptosis of acute monocytic leukemia cells in vitro

Authors: Meiqing Lei, Limin Liu, Depei Wu

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2019

Abstract

High expression of granulocyte–macrophage colony-stimulating factor (GM-CSF) receptor has been found in myelomonocytic or monocytic subtypes (M4/M5) of acute myeloid leukemia. Herein, we aimed to improve the effect of CAG [Ara-C, ACR, and G-CSF (granulocyte colony-stimulating factor)] regimen for acute monocytic leukemia by replacing G-CSF with GM-CSF. Results showed that the percentage of cells in S phase was higher with GM-CSF than with G-CSF treatment at 20 ng/mL (P < 0.05). When THP-1 and SHI-1 cells were primed with 20 ng/mL G-CSF or GM-CSF followed by Ara-C and ACR, cell proliferation rate in the CAGM (Ara-C, ACR, and GM-CSF) regimen was lower than in the CAG regimen (P < 0.05). Furthermore, CAGM regimen induced more obvious cell apoptosis than CAG regimen probably by reducing Bcl-2/Bax ratio (P < 0.05). Similar results were seen in primary cells from M5 patients. Collectively, our study suggests that priming with GM-CSF may be more effective than G-CSF in CAG regimen in acute monocytic leukemia.

Available only for authorised users

Tafuri A, Andreeff M (1990) Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4:826–834. http://www.ncbi.nlm.nih.gov/pubmed/2243506

te Boekhorst PA et al (1993) Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 7:1191–1198. http://www.ncbi.nlm.nih.gov/pubmed/7688839

Saito K et al (2000) Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 71:238–244. http://www.ncbi.nlm.nih.gov/pubmed/10846828

Li X et al (2015) Efficacy of cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen compared to FLAG regimen for adult patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Res. https://doi.org/10.1016/j.leukres.2015.08.013 CrossRefPubMed

Ornstein MC et al (2015) More is better: Combination therapies for myelodysplastic syndromes. Best Practice Res Clin Haematol 28:22–31. https://doi.org/10.1016/j.beha.2014.11.002 CrossRef

Bai A et al (1999) Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 27:259–265. https://doi.org/10.1016/S0301-472X(98)00041-1

Dartsch DC et al (2002) Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis. Apoptosis 7:537–548. https://doi.org/10.1023/A:1020647211557

Graf M et al (2004) Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol 72:89–106. https://doi.org/10.1046/j.0902-4441.2003.00184.x CrossRefPubMed

Schmetzer HM et al (1999) GM-CSF stimulates proliferation of clonal leukemic bone marrow cells in acute myeloid leukemia (AML) in vitro. Ann Hematol 78:449–455. https://doi.org/10.1007/s002770050597

10.

Faderl S et al (2003) Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood 102:630–637. https://doi.org/10.1182/blood-2002-06-1890 CrossRefPubMed

11.

Reuter C et al (1997) Differential effect of GM-CSF pretreatment on intracellular Ara-C metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts. Leukemia 11:561–571. https://doi.org/10.1038/sj.leu.2400613

12.

Thomas X et al (2010) Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 116:1725–1732. https://doi.org/10.1002/cncr.24943 CrossRefPubMed

13.

Thomas X et al (2007) Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 21:453–461. https://doi.org/10.1038/sj.leu.2404521 CrossRefPubMed

14.

Yang H et al (2017) The incidence and distribution characteristics of MLL rearrangements in Chinese acute myeloid leukemia patients by multiplex nested RT-PCR. Technol Health Care 25:S259–S265. https://doi.org/10.3233/Thc-171329 CrossRef

15.

Sironi S et al (2015) Microenvironmental hypoxia regulates FLT3 expression and biology in AML. Sci Rep 5:17550. https://doi.org/10.1038/srep17550 CrossRefPubMedPubMedCentral

16.

Nakase K et al (2015) Prognostic relevance of cytokine receptor expression in acute myeloid leukemia: interleukin-2 receptor alpha-chain (CD25) expression predicts a poor prognosis. PLoS One 10:e0128998. https://doi.org/10.1371/journal.pone.0128998 CrossRefPubMedPubMedCentral

17.

Bennett JM et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620–625. https://doi.org/10.7326/0003-4819-103-4-620

18.

Vardiman JW et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951. https://doi.org/10.1182/blood-2009-03-209262 CrossRefPubMed

19.

Arber DA et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405. https://doi.org/10.1182/blood-2016-03-643544 CrossRefPubMed

20.

Zhu HH et al (2013) Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy. Leuk Lymphoma 54:2452–2457. https://doi.org/10.3109/10428194.2013.776679 CrossRefPubMed

21.

Moon HW et al (2006) Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia. Leukemia 20:1408–1413. https://doi.org/10.1038/sj.leu.2404286 CrossRefPubMed

22.

Wang Y et al (2011) Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21). Leuk Res 35:604–607. https://doi.org/10.1016/j.leukres.2010.11.003 CrossRefPubMed

23.

Hubeek I et al (2004) The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. Int J Oncol 25:1823–1829. https://doi.org/10.3892/ijo.25.6.1823

24.

Liu L et al (2014) Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia. Int J Hematol 99:603–608. https://doi.org/10.1007/s12185-014-1528-8 CrossRefPubMed

25.

Ulukaya E et al (2011) Apoptosis: why and how does it occur in biology? Cell Biochem Funct 29:468–480. https://doi.org/10.1002/cbf.1774 CrossRef

26.

Kontos CK et al (2014) Apoptosis-related BCL2-family members: key players in chemotherapy. Anticancer Agents Med Chem 14:353–374. https://doi.org/10.2174/18715206113139990091

27.

Ren X et al (2013) Enhancement of baicalin by hexamethylene bisacetamide on the induction of apoptosis contributes to simultaneous activation of the intrinsic and extrinsic apoptotic pathways in human leukemia cells. Oncol Rep 30:2071–2080. https://doi.org/10.3892/or.2013.2684 CrossRefPubMed

Title: Priming with GM-CSF instead of G-CSF enhances CAG-induced apoptosis of acute monocytic leukemia cells in vitro
Authors: Meiqing Lei
Limin Liu
Depei Wu
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Keywords: Filgrastim
Filgrastim
Leukemia
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03857-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII

Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer

Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors

Postoperative chemotherapy as adjuvant treatment for endometrioid adenocarcinoma: early stage vs late stage

Neoadjuvant chemotherapy in patients with advanced endometrial cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer